Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like F*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Fennec Pharmaceuticals, Inc.	73077001001	PEDMARK (sodium thiosulfate injection), 12.5 g/100 mL, 100 mL vial	2022-10-11	11417.0900	None	1	3480	1	1	None	None	None	None	PEDMARK was not aquired. Comment regarding to patient estimate - Cisplatin carries the highest risk of ototoxicity among all FDA-approved platinum compounds1. About 5000 children (=18 years) are diagnosed with a solid tumor and treated with platinum-based chemotherapy every year in the United States.2,3 About 70% of these patients (~3500) are diagnosed with localized, non-metastatic disease.4 (1. Langer T et al. Trends Pharmacol Sci. 2013;34(8):458-469. 2. Ward E et al. CA Cancer J Clin. 2014;64(2):83-103. 3. National Cancer Institute. Standard populations – 19 age groups. Accessed June 10, 2022. https://seer.cancer.gov/stdpopulations/stdpop.19ages.html 4. Perkins SM et al. PLoS One. 2014;9(7):e100396. 5. Camet ML et al. Front Oncol. 2021;11:673080. FDA, US Food and Drug Administration). We estimate approximately 290 patients on a monthly based in the United States.	None
Fresenius Kabi USA LLC	63323092688	romiDEPsin Intravenous Solution Reconstituted 10 MG	2022-02-07	3168.6500	None	1	216	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219038030	Allopurinol Sodium Intravenous Solution Reconstituted 500 MG	2022-05-17	2900.0000	None	1	2000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	63323013410	PEMEtrexed Disodium Intravenous Solution Reconstituted 100 MG	2022-05-24	125.0000	None	1	788000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	63323045050	PEMEtrexed Disodium Intravenous Solution Reconstituted 500 MG	2022-05-24	625.0000	None	1	788000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219038110	Iodixanol Inj 270 MG/ML (Iodine Equivalent), 100 ML, Unit-Dose, Bottle Qty 10	2022-07-15	1021.3000	None	1	479000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219038150	Iodixanol Inj 270 MG/ML (Iodine Equivalent), 150 ML, Unit-Dose, Bottle Qty 10	2022-07-15	1489.6000	None	1	479000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219038310	Iodixanol Inj 320 MG/ML (Iodine Equivalent), 100 ML, Unit-Dose, Bottle Qty 10	2022-07-15	1134.9000	None	1	479000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219038350	Iodixanol Inj 320 MG/ML (Iodine Equivalent), 150 ML, Unit-Dose, Bottle Qty 10	2022-07-15	1566.7000	None	1	479000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219038370	Iodixanol Inj 320 MG/ML (Iodine Equivalent), 200 ML, Unit-Dose, Bottle Qty 10	2022-07-15	1930.0000	None	1	479000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219002920	Thiotepa For Inj 100 MG, 1 Each, Unit-Dose, Vial	2022-07-20	3000.0000	None	1	415000	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219008850	Gadoterate Meglumine Intravenous Solution 50 MMOL/100ML	2022-10-27	1084.9800	None	1	4165	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219055001	PRALAtrexate Intravenous Solution 20 MG/ML	2022-11-29	4981.9700	None	1	1420	None	None	None	None	None	None	None	None
Fresenius Kabi USA LLC	65219055202	PRALAtrexate Intravenous Solution 40 MG/2ML	2022-11-29	9963.9400	None	1	713	None	None	None	None	None	None	None	None